The effect of intravenous iloprost on pulmonary artery hypertension after paediatric congenital heart surgery
dc.contributor.author | Onan, Ismihan Selen | |
dc.contributor.author | Ozturk, Erkut | |
dc.contributor.author | Yildiz, Okan | |
dc.contributor.author | Altin, Husnu Firat | |
dc.contributor.author | Odemis, Ender | |
dc.contributor.author | Erek, Ersin | |
dc.date.accessioned | 2023-02-21T12:34:12Z | |
dc.date.available | 2023-02-21T12:34:12Z | |
dc.date.issued | 2016-01-01 | |
dc.description.abstract | OBJECTIVES: To investigate the effects of intravenous iloprost on pulmonary artery hypertension (PAH) in infants undergoing congenital heart surgery. METHODS: In this prospective, randomized study, the study group (n = 15) received a continuous infusion of iloprost (2.0 ng/kg/min) that was delivered immediately after weaning from cardiopulmonary bypass and continued for 72 h postoperatively. Patients in the control group (n = 12) were managed conventionally. The groups were compared in terms of postoperative data, including systolic and mean pulmonary artery (PA) pressures, PA/systemic pressure ratio, lactate level, PAH crisis, ventilation time, reintubation and lengths of intensive care unit (ICU) and hospital stay. Transthoracic echocardiography was used to assess PA pressures at 1 day, 7 days and 30 days after surgery. RESULTS: No mortality occurred. PAH crisis occurred in 2 (16.6\%) patients in the control group and 4 (26.7\%) patients in the study group (P = 0.53). Postoperative PA pressures and PA/systemic pressure ratios were similar between the groups (P > 0.05). The durations of ICU (P = 0.40) and hospital (P = 0.98) stays were similar between the groups. Echocardiographic studies demonstrated a significant decrease in postoperative PA pressures in the control (P = 0.001) and study (P = 0.0001) groups. However, no significant change was observed between the groups (P > 0.05). The Tukey multiple comparison test showed a significant decrease in PA pressures at each follow-up in both groups (P < 0.05). CONCLUSIONS: Intravenous iloprost demonstrated no additional benefit over the conventional management of infants with PAH after repair of intracardiac defects. Clinicians may prefer other alternative agents in infants with a high risk of PAH crisis. | |
dc.description.issue | 2 | |
dc.description.issue | FEB | |
dc.description.pages | 194-199 | |
dc.description.volume | 22 | |
dc.identifier.doi | 10.1093/icvts/ivv325 | |
dc.identifier.uri | https://hdl.handle.net/11443/1688 | |
dc.identifier.uri | http://dx.doi.org/10.1093/icvts/ivv325 | |
dc.identifier.wos | WOS:000372420100013 | |
dc.publisher | OXFORD UNIV PRESS | |
dc.relation.ispartof | INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY | |
dc.subject | Congenital heart surgery | |
dc.subject | Pulmonary arterial hypertension | |
dc.subject | Intravenous iloprost | |
dc.title | The effect of intravenous iloprost on pulmonary artery hypertension after paediatric congenital heart surgery | |
dc.type | Article |